Loading
Life sciences · Journal article
Current Atherosclerosis Reports · August 13, 2026
A consensus or society position rather than new primary data.
This narrative review summarizes the emerging pipeline of five Lp(a)-lowering agents across three mechanistic classes, all showing substantial reductions in Lp(a) levels and favorable short-term safety profiles in phase 1–3 trials. The critical cardiovascular outcomes trials (CVOTs) for pelacarsen and muvalaplin remain ongoing or not yet reported, limiting evidence of clinical benefit. Recent guideline recommendations for universal Lp(a) measurement reflect anticipation of regulatory approvals within 1–2 years.
Narrative literature review. Patients with elevated Lp(a), including those at high risk for atherosclerotic cardiovascular disease and calcific aortic valve stenosis; global population potentially affected if approvals occur..
Pelacarsen (ASO) reduces Lp(a) by approximately 80% via hepatic apo(a) mRNA reduction; phase 3 Lp(a) HORIZON trial results due late 2026. Three siRNA agents show very high reductions: olpasiran >95%, lepodisiran 93.9% sustained over 12 months post-single dose, zerlasiran 96.4%. Muvalaplin, an oral small-molecule inhibitor, achieves up to 85.8% Lp(a) reduction in phase 2 KRAKEN trials; phase 3 MOVE-Lp(a) CVOT underway.
Long-term safety and durability of CRISPR/Cas9 approach unknown; only phase 1 data reported for CTX320. All agents reported good safety so far across disclosed trial phases.
Clinicians should be aware that Lp(a) measurement is now recommended universally and that multiple late-stage therapies targeting Lp(a) reduction are approaching regulatory decision points. However, cardiovascular outcome benefits remain unproven pending CVOT results; treatment decisions should await hard endpoint data.
A comprehensive narrative review synthesizing phase 1–3 trial data, regulatory updates, and pipeline information to inform clinical and research practice regarding emerging Lp(a) therapies.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should be aware that Lp(a) measurement is now recommended universally and that multiple late-stage therapies targeting Lp(a) reduction are approaching regulatory decision points. However, cardiovascular outcome benefits remain unproven pending CVOT results; treatment decisions should await hard endpoint data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Purpose of Review Lipoprotein(a) [Lp(a)] is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Plasma Lp(a) levels are 70–90% heritable, largely unresponsive to lifestyle changes, and poorly controlled with typical lipid-lowering drugs such as statins and PCSK9 inhibitors. The development of powerful RNA-based therapies offers a new chance to specifically target and significantly lower Lp(a). We examined available phase 1–3 trial data, regulatory updates, and trial registries up to mid-2026 to provide an overview of the current pipeline, ongoing cardiovascular outcomes trials (CVOTs), and new mechanistic and genomic methods. Recent Findings Five agents across three mechanisms have reached late-stage development. Pelacarsen, a GalNAc-conjugated antisense oligonucleotide (ASO), reduces Lp(a) by about 80% via hepatic apo(a) mRNA reduction and is the subject of the phase 3 Lp(a) HORIZON trial, with results due in late 2026. Three small interfering RNA (siRNA) drugs, olpasiran (> 95% reduction, OCEAN(a)-Outcomes), lepodisiran (93.9% reduction lasting over 12 months after one dose, ACCLAIM-Lp(a)), and zerlasiran (96.4% reduction), allow quarterly or possibly yearly dosing. Muvalaplin, the first oral small-molecule Lp(a) inhibitor, interferes with apo(a)-ApoB particle formation and reduces intact Lp(a) by up to 85.8% in phase 2 KRAKEN trials; its phase 3 CVOT (MOVE-Lp(a)) is underway. Additionally, CRISPR/Cas9-based liver gene editing targeting the LPA gene (CTX320) has entered phase 1 studies. All agents have shown good safety so far. Summary The Lp(a) treatment landscape has moved from basic science to an active late-stage clinical pipeline. Positive outcomes from these CVOTs could lead to regulatory approvals and guideline updates affecting hundreds of millions of high-risk patients globally. Recent guidelines now recommend universal Lp(a) measurement, in anticipation of more effective therapies becoming available within the next 1 to 2 years.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.